Hyperuricemia Market Research Report 2030 | Hyperuricemia Market

 What is Hyperuricemia?

Hyperuricemia occurs when there is an excessive amount of acid in your blood. High uric acid levels can cause several diseases, including a painful sort of arthritis called gout. Elevated acid levels also are related to health conditions like heart condition, diabetes, and kidney disease.

DelveInsight launched a new report titled "Hyperuricemia Market Report 2030” which delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and market trends within the 7MM.

Hyperuricemia Sign & Symptoms

Only about one-third of individuals with hyperuricemia experience symptoms referred to as asymptomatic hyperuricemia. Although hyperuricemia isn't a disease, if uric acid levels remain high, over time they will cause several diseases.

In another case, uric acid crystals can develop kidney stones. Counting on the dimensions of the kidney stone, symptoms can include severe lower back pain, blood in urine, fever, nausea, and vomiting, foul-smelling urine, stomach aches.

Got queries? Click here to read more insights @ Hyperuricemia Market Outlook

Hyperuricemia Epidemiology Insights:

The Hyperuricemia Epidemiology section of the report includes information on the diagnosed patient pool, trends, and assumptions used.

●     According to the report, it's estimated the maximum amount is 21% of the overall population and 25% of hospitalized patients have asymptomatic hyperuricemia.

●     According to the survey, when using a common cut-off value hyperuricemia is seen to be twice as common in men as shown in other studies.

●     According to the study, the prevalence of hyperuricemia increased with age, with the very best prevalence (36.8%[3.2 million]) among individuals ages 80 years or older.

For each of the seven major countries, the Hyperuricemia epidemiology section provides information on historical and present Hyperuricemia patient pools, as well as predicted trends.

Read more @ Hyperuricemia Epidemiology Insights

Hyperuricemia Market Insights

The Hyperuricemia market is estimated to increase to USD XX Million in 2030. The major reason behind the market upsurge is the launch of emerging therapies.

Diagnosis and treatment of Hyperuricemia still remain challenging as most of the cases are asymptomatic. Some emerging drugs are LC350189, SAP-001, Verinurad, and major key competitors are Shanton Pharma, LG Chem, AstraZeneca.

According to DelveInsight, the Hyperuricemia Market in 7MM is predicted to vary within the study period 2018-2030.

Hyperuricemia Emerging Therapy Assessment

Key pharma players committed to the development of therapies for Hyperuricemia patients are: 

  1. Verinurad     by AstraZeneca
  2. SAP-001     by Shanton
  3. LC350189     by LG Chem
  4. And     others.

Verinurad by AstraZeneca

Verinurad, a selective URAT1 inhibitor, is under development by AstraZeneca. It is an SLC22A12 protein inhibitor that has demonstrated high potency in inhibiting URAT1 and has shown significant sUA lowering in humans at doses as low as 2.5 mg.

SAP-001 by Shanton

Shanton is currently actively developing SAP-001 for addressing gout metabolic syndrome. Its drug SAP-001 is a new investigational Uric Acid Transporter 1 (URAT1) inhibitor for the chronic management of hyperuricemia and reduced frequency and severity of gout flare in patients with gout.

LC350189 by LG Chem

LC350189 by LG Life Sciences is under trial for the management of hyperuricemia in gout patients. LG chem initiated a phase II clinical trial to assess the efficacy and safety of three different doses of LC350189.

The Hyperuricemia emerging therapy assessment of the report encloses an in-depth analysis of Hyperuricemia marketed drugs and late-stage pipeline drugs.

Visit our repository of reports @ DelveInsight Report Store

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Comments

Post a Comment

Popular posts from this blog

Beta-thalassemia Market Poised for Significant Growth with Novel Therapies and Rising Prevalence

The Beta-thalassemia market is set to experience remarkable growth in the coming years, driven by the increasing prevalence of the condition and the anticipated launch of innovative therapies. Leading players in the pharmaceutical and biotech industries, including Acceleron Pharma, Agios Pharmaceuticals, Bluebird Bio, and CRISPR Therapeutics, are working diligently to address unmet medical needs and expand treatment options. Download our sample pages @ https://www.delveinsight.com/report-store/beta-thalassemia-market?utm_source=report&utm_medium=promotion&utm_campaign=kpr Market Dynamics and Key Drivers Beta-thalassemia, a hereditary blood disorder caused by mutations in the HBB gene, results in reduced or absent synthesis of beta-globin chains in hemoglobin. This condition affects millions worldwide, with significant prevalence in regions such as the United States, Europe, and Asia. Recent advancements in diagnostics and a heightened focus on genetic counseling have contribute...
Read more

Growth of the Candidemia Market: Drivers, Developments, and Future Outlook (2024-2034)

Candidemia , a bloodstream infection caused by Candida species, poses significant health challenges, particularly among individuals with weakened immune systems. The global candidemia market is projected to experience a compound annual growth rate (CAGR) of 3.16% from 2024 to 2034. citeturn0search0 Market Drivers: Increasing Incidence: The rising number of immunocompromised patients, including those with HIV/AIDS, cancer, or organ transplants, has led to a higher prevalence of candidemia. Advancements in Diagnostics: The adoption of advanced diagnostic techniques, such as molecular assays and biomarker identification, facilitates swift and accurate detection of candidemia, enabling timely intervention and improved patient outcomes. Innovative Therapeutics: The development of novel antifungal medications and immune-based therapies offers enhanced efficacy and reduced adverse effects, contributing to market growth. To know more about candidemia market drivers, visit https://www.delvei...
Read more

Unlocking the Facts: C-Met Mutated Non-Small Cell Lung Cancer Epidemiology, Market Trends, and Leading Players

What is C-Met Mutated Non-small Cell Lung Cancer ? C-Met (also known as MET) is a gene that codes for a protein called the "hepatocyte growth factor receptor" (HGFR) or c-Met receptor. This receptor plays a crucial role in regulating cell growth, survival, migration, and invasion. When the c-Met gene is mutated, it can lead to the abnormal activation of signaling pathways that promote cancer development and progression. How is C-Met Mutated Non-small Cell Lung Cancer epidemiology segmented? C-Met Mutated Non-small Cell Lung Cancer epidemiology is segmented as C-Met Mutated Non-small Cell Lung Cancer Total Incident Cases, Age-specific C-Met Mutated Non-small Cell Lung Cancer cases, Gender-specific C-Met Mutated Non-small Cell Lung Cancer Cases, Stage-specific C-Met Mutated Non-small Cell Lung Cancer incident cases, Type-specific C-Met Mutated Non-small Cell Lung Cancer incident cases, and Total Treated C-Met Mutated Non-small Cell Lung Cancer Cases. What is the C-Met Mutated...
Read more